Sun Yat-Sen University Cancer Center
Sun Yat-Sen University Cancer Center
Explore linked clinical trials.74 results ยท Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Not applicable | 2026-10-09 | NCT03108196 | |
| Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Not applicable | 2026-10-08 | NCT07866612 | |
| A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal disorder, neoplasm | Recruiting | Phase 2 | 2026-10-07 | NCT07863141 | |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers | Advanced Solid Tumor | Enrolling by invitation | Phase 1 | 2026-09-21 | NCT06169579 | |
| Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction | Cisplatin Adverse Reaction; Cisplatin Nephrotoxicity | Not yet recruiting | Phase 1 | 2026-09-17 | NCT07824843 | |
| Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma | Non-clear Cell Renal Cell Carcinoma | Active, not recruiting | Phase 2 | 2026-09-16 | NCT05831891 | |
| Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer | Breast Cancer Metastatic | Active, not recruiting | Phase 2 | 2026-09-16 | NCT05759572 | |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT07791758 | |
| "Xijiang Project" Screening Cohort for NPC | DNA Virus Infections, Epstein-Barr virus infection, Head and Neck Neoplasms, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, Tumor Virus Infections, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, viral infectious disease | Recruiting | Not stated | 2026-09-01 | NCT06787456 | |
| ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC | Neoplasm, Residual, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Not stated | 2026-08-31 | NCT05198154 | |
| A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | Cirrhosis, Familial, with Pulmonary Hypertension, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-28 | NCT07632235 | |
| Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Not stated | 2026-08-27 | NCT07137052 | |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | Recruiting | Phase 2 | 2026-08-27 | NCT06783647 | |
| MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Phase 2 | 2026-08-05 | NCT07677475 | |
| Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-23 | NCT07632365 | |
| Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma | Thoracic Esophageal Squamous Cell Carcinoma | Recruiting | Not applicable | 2026-07-21 | NCT04174079 | |
| AI-Driven Tumor Response Evaluation for Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Not stated | 2026-07-08 | NCT07685548 | |
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial | Capecitabine; Local Advanced Rectal Cancer; Oxaliplatin; PCSK9 Inhibitor; PD-1 Inhibitor; RCT; Radiotherapy | Not yet recruiting | Phase 3 | 2026-07-07 | NCT07686796 | |
| A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) | Previously Untreated Peripheral T-Cell Lymphoma | Not yet recruiting | Phase 2 | 2026-06-30 | NCT07676175 | |
| Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC) | renal pelvis/ureter urothelial carcinoma | Recruiting | Not applicable | 2026-06-25 | NCT07321210 | |
| Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Not applicable | 2026-06-25 | NCT07321197 | |
| RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 3 | 2026-06-04 | NCT07590024 | |
| Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Not stated | 2026-06-03 | NCT07618078 | |
| Spectral Precise Image-Colon Cancer | Colon Cancer Patients | Not yet recruiting | Not stated | 2026-06-02 | NCT07620444 | |
| INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma | Ovarian Clear Cell Carcinoma | Recruiting | Phase 3 | 2026-05-18 | NCT07002346 |